Efficacy and safety of a GABAergic drug (Gamalate® B6): effects on behavior and cognition in young adults with borderline-to-mild intellectual developmental disabilities and ADHD

BACKGROUND: We evaluated Gamalate® B6 (GB6) in patients with borderline intellectual functioning (BIF) or mild intellectual development disability (IDD). PATIENTS AND METHODS: This was a prospective phase IV observational pilot study in 30 patients who underwent neuropsychological evaluation during...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Drugs Context
Autores principales: Novell, Ramón, Esteba-Castillo, Susanna, Rodriguez, Emili
Formato: Artigo
Lenguaje:Inglês
Publicado: BioExcel Publishing Ltd 2020
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7048157/
https://ncbi.nlm.nih.gov/pubmed/32158489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212601
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares